Dyne to seek accelerated approval of DMD drug on Phase I/II data
Dyne Therapeutics intends to submit a biologics licence application to the FDA for accelerated approval in Q2 2026.
10 December 2025
10 December 2025
Dyne Therapeutics intends to submit a biologics licence application to the FDA for accelerated approval in Q2 2026.
Merging industry-leading business intelligence & award-winning journalism, this is an unrivalled opportunity for engagement with B2B professionals across a network of 40+ leading media websites.
Steer your business strategy with key data and insights from our latest market research reports and company profiles. Not ready to buy? Start small by downloading a sample report first.
Give your business an edge with our leading industry insights.